Why the study?
Does sustained-release acebutolol provide equivalent pharmacokinetics and beta-blockade compared to conventional acebutolol in healthy volunteers?
Does sustained-release acebutolol provide equivalent pharmacokinetics and beta-blockade compared to conventional acebutolol in healthy volunteers?
Sustained-release acebutolol (500 mg/day) provides equivalent beta-blockade to conventional acebutolol (200 mg tid) in healthy volunteers.
Answers are grounded in this paper and cite their sources.
SR acebutolol equivalence in volunteers supports formulation testing; leaves open translation to patients with cardiovascular disease.
Pharmacokinetics and the degree of beta-blockade of sustained release (SR) acebutolol (500 mg/day) and conventional acebutolol (200 mg tid) were examined after the first oral dose and after 10 days of treatment in ten healthy volunteers. After the first dose, acebutolol Cmax did not significantly differ between the two formulations; however, on day 10 acebutolol Cmax was significantly higher after SR formulation. Cmax of diacetolol, the major metabolite, did not differ between SR and conventional acebutolol neither on day 1 nor on day 10. The dose-corrected relative bio-availability of acebutolol was not different from 100% on day 1 and day 10; however the dose-corrected diacetolol AUC, SR/conventional ratio, was significantly lower than 100% on days 1 and 10. Both acebutolol preparations exerted a significant reduction in exercise tachycardia over 24 h on day 1 and day 10; however, conventional acebutolol exhibited a greater reduction 24 h after the first dose. Exercise-induced increase in systolic blood pressure was similarly inhibited by both treatments except for 24 h after the first dose when systolic blood pressure was significantly higher with SR than with conventional acebutolol. The percent reduction in heart rate during exercise was linearly correlated with log acebutolol plasma concentrations for each treatment regimen. These results suggest that beta-blockade exerted by SR acebutolol in healthy volunteers is equivalent to that of conventional acebutolol.
No takes yet. Share an insight, caveat, or question.
Fleurot et al. (1991) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: